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The gender difference in cancer susceptibility is one of the most consistent findings in can-
cer epidemiology. Hematologic malignancies are generally more common in males and this
can be generalized to most other cancers. Similar gender differences in non-malignant dis-
eases including autoimmunity, are attributed to hormonal or behavioral differences. Even in
early childhood, however, where these differences would not apply, there are differences in
cancer incidence between males and females. In childhood, few cancers are more common
in females, but overall, males have higher susceptibility. In Hodgkin lymphoma, the gender
ratio reverses toward adolescence.The pattern that autoimmune disorders are more com-
mon in females, but cancer and infections in males suggests that the known differences in
immunity may be responsible for this dichotomy. Besides immune surveillance, genome
surveillance mechanisms also differ in efficiency between males and females. Other obvi-
ous differences include hormonal ones and the number of X chromosomes. Some of the
differences may even originate from exposures during prenatal development. This review
will summarize well-documented examples of gender effect in cancer susceptibility, dis-
cuss methodological issues in exploration of gender differences, and present documented
or speculated mechanisms. The gender differential in susceptibility can give important
clues for the etiology of cancers and should be examined in all genetic and non-genetic
association studies.
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Gender differences in susceptibility to a disease is a very useful
piece of information that can be used to develop a causal hypoth-
esis for the disease, or to define subgroups at highest risk for
preventive action (Zahm and Fraumeni, 1995). The gender dif-
ferential in cancer incidence rates is comparable to ethnic and
racial disparity in magnitude, and yet, most studies fail to look for
it. In genetic epidemiologic studies, if examined, it is common that
genders do not have equal susceptibility to diseases. Exploration
of gender disparity in disease susceptibility has not become com-
mon practice even in diseases that show sex differential in their
incidence rates. Here, we will document this phenomenon in can-
cer susceptibility with examples, discuss possible mechanisms, and
review basic methodology for its examination.
DESCRIPTIVE EPIDEMIOLOGY OF GENDER DIFFERENCES IN
CANCER SUSCEPTIBILITY
Epidemiology is sometimes considered to be an unhealthy science
because of frequently documented inconsistencies in findings and
replication failures. It is relatively infrequent that a finding will
be sustained in follow-up studies. However, gender differential in
cancer occurrence is one very consistent finding in descriptive epi-
demiology. For a very long-time, it has been recognized that males
are more prone to develop cancer, and particularly hematologic
malignancies (Ashley, 1969; Pearce and Parker, 2001; Cartwright
et al., 2002; Cook et al., 2009; Edgren et al., 2012). Prognosis in
childhood cancers is also worse in boys than girls (Eden et al.,
2000), and second malignancies occur more frequently in boys
who have survived cancer (Devarahally et al., 2003). In adult
malignancies, again, males have worse overall survival and higher
mortality rates (Molife et al., 2001; Cook et al., 2011).
GENDER DIFFERENCES IN UNITED STATES DATA
The sex differential in primary cancer susceptibility can be quan-
tified by comparison of incidence rates in males and females.
The latest analysis of the National Cancer Institute Surveillance
Epidemiology and End Results (SEER) database showed that inci-
dence rates per 100,000 people and age-adjusted to the 2000
US standard population for all cancers in the United States for
2004–2008 are 553.0 for males and 416.5 for females yielding an
incidence rate ratio (IRR) of 1.33 for all cancers (Siegel et al.,
2012). Although these numbers are inclusive of sex-specific can-
cers such as breast and prostate, their exclusion does not alter the
IRR (1.35). Likewise, the lifetime probability of developing can-
cer is 44.85% for males, and 38.08% for females. The probability
is higher for males despite a shorter life expectancy. The same
analysis also showed that the cancer mortality rates were higher in
males: 223.0 versus 153.2 (ratio= 1.46). Most importantly, the
common cancers have the highest male-to-female (M:F) ratio:
colorectal cancers: 1.35; lung and bronchus: 1.52; non-Hodgkin
lymphoma (NHL): 1.44; (urinary) bladder: 4.0. Another recent
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analysis of SEER identified Kaposi sarcoma as having the highest
M:F IRR (28.7; Cook et al., 2009). Other than breast cancer, which
rarely occurs in males, only a few cancers are more common in
females. Gall bladder, anus, and thyroid tumors consistently show
an M:F ratio less than 1.0 (Cook et al., 2009). In Table 1, we present
sex-specific incidence rates in the US and worldwide for selected
cancers.
GENDER DIFFERENCES ARE SEEN WORLDWIDE
The increased M:F ratio for incident cancer is not unique to a
particular country, population, or region. The analysis of age- and
sex-specific cancer incidence data from Cancer Incidence in Five
Continents provided by the International Agency for Research on
Cancer (IARC) documented the universal nature of the sex dis-
parity in cancer (Edgren et al., 2012). In 32 of 35 cancer sites,
males had a higher incidence rates consistently across geograph-
ical regions. The three exceptions were thyroid, gallbladder, and
anus cancer that had higher incidence rates in females. The most
drastic occurrences of male excess were noted for laryngeal and
hypopharyngeal cancer, which showed around sixfold excess in
males. In this global dataset, sex differences were statistically sig-
nificant at all sites (P < 0.0001). When age in adult life is taken
into account, some variation is evident, especially for skin can-
cer and salivary gland cancer with both becoming more common
in males in increasing age groups. NHL, along with its glob-
ally consistent high M:F ratio, showed consistency also in all age
groups: M:F ratio equals 1.42 with little variation in age groups
(range= 1.36–1.59).
CHILDHOOD CANCERS SHOW GENDER DIFFERENCES TOO
In childhood cancer, males are again at a higher risk than females.
The sex differential in the incidence of childhood cancer is well
established and consistent worldwide (Ashley, 1969; Greenberg
and Shuster, 1985; Linet and Devesa, 1991; Pearce and Parker,
2001; Cartwright et al., 2002; Desandes et al., 2004). The M:F ratio
Table 1 | Selected cancers with the highest and lowest male-to-female
ratios*.
Cancer Male-to-female ratio
SEER (USA) IARC (world)
Larynx 5.17 6.36
Hypopharynx 4.13 5.75
Kaposi sarcoma 28.7 4.87
Lip 7.16 4.25
Urinary bladder 3.92 4.12
Gall bladder and biliary tract 0.57 0.94
Anus 0.81 0.85
Thyroid 0.39 0.33
*SEER data from Cook et al. (2009), Siegel et al. (2012); GLOBCAN (world) data
from Edgren et al. (2012). In SEER data, all ages combined, the cancer burden
was higher in males than females for total cancer (male-to-female incidence rate
ratio=1.37; 95% CI=1.37–1.38. For the world data, all sex differences were
statistically significant (P<0.0001).
for all incident cancers is around 1.2. Exceptions to the male excess
in childhood cancer include infant leukemia, thyroid carcinoma,
malignant melanoma, and alveolar soft part sarcoma. As in adults,
NHL shows a stable male excess in all age groups during childhood
and adolescent period (range= 1.7–3.2), whereas Hodgkin lym-
phoma (HL) shows an interesting age-dependent variation in its
M:F ratio (Ries et al., 1999). The overall incidence of HL in children
is greater in females than in males (M:F ratio= 0.8), but the sex
distribution is age-dependent, with the striking M:F ratio in HL
in younger ages when the disease is rare reversing for adolescents
when it becomes more common (Spitz et al., 1986). The SEER
data from 1990 to 1995 period show M:F ratios of 5.3 (<5 year),
1.4 (5–9 year), 1.1 (10–14 year), and 0.8 (15–19; Ries et al., 1999).
GENDER DIFFERENCES IN INFECTIONS ARE SIMILAR
There are other conditions that males and females show different
levels of susceptibility. Any corollary finding may also help develop
etiologic hypotheses. The most relevant one is the increased inci-
dence of infections in males in humans and animals, and in
controlled animal experiments (Washburn et al., 1965; Schlegel
and Bellanti, 1969; Purtilo and Sullivan, 1979; Green, 1992; Read
et al., 1997; Klein, 2000; Wells, 2000). Women also survive sepsis
at higher rates than men (Schroder et al., 2000). This common-
ality between cancer and infections suggest that the difference
may lie in the male and female immune system since immune
surveillance mechanisms are similar against infectious agents and
cancer cells. Although infections are generally more common in
males, morbidity and mortality rates may be higher in females
for some infections such as HIV infection and influenza, espe-
cially in those where immune activation and cytokine storm have
deleterious effects on prognosis (Klein et al., 2012). The greater
severity of post-infectious immunopathologic events in females is
due to their ability to generate higher proinflammatory cytokine
and chemokine responses than males. This should not be confused
with the lower primary susceptibility of females to infections due
to enhanced immune response capability.
GENDER-SPECIFIC ASSOCIATIONS IN CANCER GENETIC
EPIDEMIOLOGY
Not just cancer, but some other common diseases also show some
gender differential. It is important to recognize and use it to gain
insight into disease biology. In addition to a systematic explo-
ration of the mechanisms underlying physiological differences
between sexes using genetical genomics (Li et al., 2008), genetic
epidemiology can be used to probe disease biology (Hindorff et al.,
2009). Genetic associations with sex-specificity should be able to
shed some light on the pathogenesis of diseases showing such
associations. While there has been some encouragement by the
government agencies such as the US National Institutes of Health
and Institute of Medicine, and several journals (Arnold, 2000;
Blaustein, 2012), not much progress has been noted in explor-
ing sex-specificity of genetic associations. Most of the papers that
reported sex-specific genetic associations have not stood the test
of time (Patsopoulos et al., 2007). In a survey of prominent claims
of sex differential in genetic associations with common diseases,
most of the claims were found to be spurious or insufficiently
supported by the data presented.
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AUTOSOMAL CHROMOSOMES VERSUS SEX CHROMOSOMES
There seems to be a general consensus that gene expression changes
are the most common intermediate phenotype between genetic
variants and modification of disease risk (Nica and Dermitza-
kis, 2008; Cookson et al., 2009; Murphy et al., 2010). It is only
natural that any sex differential in gene expression levels should
concern genes encoded in sex chromosomes. Even X chromosome
genes show variation in their expression among females (Car-
rel and Willard, 2005). Most studies have found that autosomal
genes make up the majority among those with sex-biased expres-
sion (Ostrer, 2001; Rinn et al., 2004; Mank et al., 2010; Arnold
and Lusis, 2012). Thus, the potential of any genetic variant to
yield a gender-specific association does not depend on its genomic
location. A recent re-analysis of GWAS top hits for common dis-
orders have yielded gender-specificity for some of them (Liu et al.,
2012), despite that only the variants that were found significantly
associated in the original overall analyses were included in the
re-analysis. It is hoped that these initial results will encourage
researchers to re-analyze complete datasets to uncover sex-specific
associations, which may have been totally missed if males and
females had associations in opposite directions (see next section).
We have screened the literature for sex-specific genetic asso-
ciations with cancer susceptibility, and provided a list of selected
examples in Table 2.
METHODOLOGICAL ISSUES IN EXAMINATION OF GENDER
DIFFERENCE IN CANCER SUSCEPTIBILITY
Exploration of gender differences does not require any special
method other than those already being used to examine homo-
geneity of effect size in different strata (effect modification). Treat-
ing gender as an environmental factor and testing associations
for interaction with gender is one way of identifying associations
modified by gender. A significant interaction may indicate either
variable strength of the associations, or opposite direction of the
associations in males and females. Analysis after stratification by
gender clarifies the situation, and unravels any gender-specificity
which may otherwise go unnoticed, especially if the association is
with decreased risk in one gender, and with increased risk in the
other.
EXAMINATION OF GENDER DIFFERENCES IS A SIMPLE PROCESS
In cancer susceptibility, the role played by the environment is
much greater than that of genetics (Lichtenstein et al., 2000; Le
Marchand, 2005; Hemminki et al., 2006). It is therefore impor-
tant to remind ourselves that genetic factors are more likely to
be modifiers of susceptibility rather than primary determinants
of susceptibility (Le Marchand, 2005). It has been suggested that
genetic susceptibility studies in cancer would yield more meaning-
ful results if performed in high risk subpopulations (Le Marchand,
2005). Likewise, if either sex has a higher risk as descriptive
epidemiology strongly suggests, analyzing males and females sepa-
rately should produce useful results. Discussions of various issues
regarding the subgroup analysis or losing statistical power do not
necessarily apply to the analysis of results after stratification by
sex. Literature is full of examples unraveling gender-specific asso-
ciations only after stratifications which were not evident in overall
analysis (Table 2). Given that the re-analysis of even the markers
already associated with diseases in the overall analysis can show
sex-specific associations (Liu et al., 2012), a similar approach for
candidate markers even if they do not show any association in the
whole sample should be common practice. The benefits of uncov-
ering hidden associations is likely to outweigh any concern over
multiple comparisons, which can be handled either statistically by
a variety of methods (Rice et al., 2008) or epidemiologically by
replication (Hattersley and McCarthy, 2005; Siontis et al., 2010).
The concerns over losing statistical power when the sample is split
into males and females do not take into account that in a gender-
specific association situation, not splitting the sample causes loss
of power. With the increasing effect size in the sex which shows the
association exclusively, the statistical power will be much higher
than that in the pooled sample. Even some of the missing heri-
tability in GWAS (Manolio et al., 2009) may be identified through
routine use of sex-specific analysis, as the post hoc analysis done in
one study suggested (Liu et al., 2012).
GENDER DIFFERENCES CAN BE FOUND FREQUENTLY FROM GENETIC
LINKAGE TO METABOLOMICS STUDIES
There are published reports on the success of taking gender into
account in data analysis. As listed in Table 2, genetic associations
may differ between males and females when explored. Likewise,
genetic linkage studies have yielded different gender-specific link-
age results in inflammatory bowel disease (Fisher et al., 2002) and
a number of complex traits such as blood LDL, HDL levels, and
systolic blood pressure (Weiss et al., 2006). In the latter study,
heritability values also differed for those traits between males
and females. It is now becoming a common finding in genetical
genomics studies that expression levels of even autosomal genes
differ between males and females (van Nas et al., 2009). Most
recently, even a metabolomics study revealed gender differences
in metabolite levels and their correlations with genetic markers
(Mittelstrass et al., 2011). Thus, it is clear that when explored, gen-
der differences are possibly there to be revealed. Gender could and
should be considered an environmental variable that can modify
both penetrance and expressivity of a wide variety of traits (Weiss
et al., 2006).
NOT ALL GENDER DIFFERENCES ARE REAL
A detailed survey of the biomedical literature for reported gen-
der differences in genetic associations highlighted many prevailing
problems (Patsopoulos et al., 2007). Most claims were not docu-
mented sufficiently. A common example was finding a smaller
P value in one group and claiming a gender differential without
assessing the difference statistically. This situation may well arise
when one gender is underrepresented in the sample and result-
ing in lower statistical power. Many spurious claims have also
been identified. These included claims of sex differences based on
comparisons of male and female cases only, or comparisons of a
certain genotype ignoring other genotypes of the same locus, or
comparisons of one gender against a subgroup of the other. It is
therefore important that the search for the gender effect should
not be turned into a fishing expedition. It is best just to simply
analyze the whole sample for each gender separately, and if there is
any indication of a differential, to assess the statistical interaction
formally.
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Table 2 | Examples of genetic associations with cancer susceptibility exclusive to males or females.
Cancer Locus/SNP PubMed ID
Various cancers MDM2 (SNP309; accelerated age of diagnosis in females) 17322917
Childhood acute lymphoblastic leukemia (ALL) MDM2 (SNP309; accelerated age of diagnosis in females) 19837266
Childhood ALL HLA-DRB4 (rs2395185; risk association in males only) 10397736 (Kennedy et
al., unpublished data)
Childhood ALL HLA-DRA (rs3135388), HLA-C (rs9264942; risk and protective associations
in females only)
21067287
Childhood ALL HSPA1B (rs1061581; stronger protective association in males) 20012387
Childhood ALL IFNG (rs2069727; protective association in males only) 21067287
Childhood ALL IRF4 (rs12203592; risk association in males only) 19897031
Childhood ALL HFE (rs807212; protective association in males only) 19806355
Childhood ALL CYP1A1 (rs1799814), NAT1/NAT2 (associations in females
“CYP21A2/protective” and males “NAT1–NAT2/risk” only)
10953966
Childhood ALL ARID5B (rs10994982 and rs10740055; risk association in males only) 20460642
Acute myeloblastic and lymphoblastic leukemia NQO1 (rs1800566) and GSTT1 (deletion; stronger risk association in males) 17339179
Nasopharyngeal cancer MICA (short tandem repeat polymorphism and deletion; increased
MICA*A9 and *A5.1 frequencies in males; increased MICA/HCP5 deletion
in males)
16547745; 21536588
Lung cancer VEGF (haplotypic risk association in males only) 18223238
Lung cancer MTHFR (risk and protective associations in females only) 15941959
Lung cancer CYP1A1 (stronger risk association in males) 12594823
Lung cancer GSTM1 (stronger risk association in females) 9855008
Lung cancer Chromosome 15q25 region (rs3841324; protective association in females
only)
22028403
Upper aerodigestive tract cancers Chromosome 15q25 region (rs16969968; risk association in females only) 21335511
Colorectal cancer GSTM1 and GSTM3 (stronger associations in males) 11408349
Colorectal cancer APOE (risk association in females only) 12529167
Colorectal cancer NAT2 (risk association in females only) 19107910
Pancreas cancer NAT1 (risk association in males only) 18499698
Bladder cancer SULT1A1 (rs9282861; stronger protective association in females) 14643027
GENDER DIFFERENCES APPEAR IN DIFFERENT WAYS
It may sound implausible, but there are examples of genetic asso-
ciations in opposite directions in each sex (Ober et al., 2008).
One of the most remarkable gender-specific associations con-
cerns the recombination rates in the human genome (Kong et al.,
2008), which is itself a sexually dimorphic trait (Broman et al.,
1998). A GWAS design was used to examine the genetic basis of
this recombination rate differences. SNPs in the RNF212 gene
showed associations with their statistical significance exceeding
genome-wide threshold level both in males and females sepa-
rately. However, the associations were in opposite directions. The
associations observed were real and confirmed in a second study
cohort (Kong et al., 2008). The presence of similar robust and
replicated associations of IFNG in asthma (Loisel et al., 2011) and
RELN in schizophrenia (Shifman et al., 2008) further confirms
the reality of gender-specific associations. There are different pat-
terns of gender differences in genetic susceptibility (Ober et al.,
2008). The IFNG association in asthma is particularly intriguing
in that the association is with the heterozygous genotype, but in
opposite directions in males and females (Loisel et al., 2011): het-
erozygote advantage in females and heterozygote disadvantage in
males.
STATISTICAL ADJUSTMENT IS NOT SUFFICIENT
Although not highlighted by the authors of the survey, a com-
mon problem in handling the gender effect on susceptibility is
adjusting the results for the gender and declaring no change as
evidence for the lack of gender difference in susceptibility. This
is commonly done, but it rules out confounding by sex, which
is not equivalent to gender difference in susceptibility. If adjust-
ment for gender does not change the results, gender can be ruled
out as a confounder, but these results say nothing about possi-
ble interaction with gender. To rule out interaction of association
results with gender, which is the indication of a gender difference
in susceptibility, simple statistical methods are available. These
include logistic regression with genotype-gender interaction term
(Nick and Campbell, 2007) and tests for homogeneity of odds
ratios across different strata (Paul and Donner, 1989). Recently, a
permutation-based method to compute gender differenceP values
has been developed and used successfully (Liu et al., 2012).
In summary, to uncover gender differences in genetic associa-
tion studies, the design should include both males and females in
the study sample, the information on gender should be collected
or this information should be obtained by genotyping the samples
(Gold et al., 2001), and interaction with gender difference should
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be assessed by stratified analysis. Analysis of males and females
separately is the only way to unmask an association that shows
gender difference. In a simple case-control study when the out-
come is a binary variable, exploration of genotype, and gender
interaction by logistic regression is a mostly neglected, but rather
straightforward approach. For more complicated designs and for
quantitative outcomes, methods developed to analyze gene and
environment interactions can be used as if gender was a binary
environmental exposure variable (Thomas, 2010).
MECHANISM OF GENDER DIFFERENCES IN CANCER
SUSCEPTIBILITY
In some diseases, the gender disparity can be explained easily:
mutations in X-linked immune system genes cause congenital
forms of immune deficiencies such as X-linked combined immun-
odeficiency and Wiskott–Aldrich syndrome almost exclusively
in males due to the sex chromosome composition differences
between males and females. On the other hand, most smoking-
related diseases, like chronic obstructive pulmonary disease, are
historically more common in males. It is therefore differences in
either an endogenous biological determinant or environmental
exposure that cause the disparity. In cancer susceptibility, however,
the reasons for the gender difference remain enigmatic (Edgren
et al., 2012).
Several factors may contribute to the development of gender
disparity in general disease susceptibility, including sex hormones,
genetic differences, environmental causes (Zahm and Fraumeni,
1995; Klein, 2000; Cook et al., 2009), gender-linked differences
in the skin (Giacomoni et al., 2009), epigenetics (Kaminsky
et al., 2006; Gabory et al., 2009), and as more recently suggested,
microchimerism (Ober et al., 2008; Ghazeeri et al., 2011), and
autophagy (Lista et al., 2011). The common belief is that the male
excess in cancer incidence is due to variation in environmental
and occupational exposures, including smoking, diet, and sun-
light exposure. Environmental exposures indeed dominate overall
cancer risk, but environmental variations alone cannot explain
the sex differential in cancer risk. Differences in environmental
exposures for each cancer that is more common in either sex are
known for few cancers but not as a general phenomenon (Zahm
and Fraumeni, 1995). Any differential exposure would have to
apply to young adults and even children, who have little cumula-
tive exposure to environmental genotoxins. Thus, if not all, some
contribution to male excess in cancer is expected to come from
genetic factors.
PHYSIOLOGICAL DIFFERENCES BETWEEN MALES AND FEMALES
There are known physiological differences that may explain why
there is a disparity in the incidence of certain cancers (Table 3).
Hepatocellular carcinoma (HCC) is more common in males and
one reason for this difference may be higher interleukin-6 (IL-6)
levels in males. IL-6 aids progression of HCC and IL-6 produc-
tion is inhibited by estrogens, which lower the risk of HCC in
females (Naugler et al., 2007; Yeh and Chen, 2010). On the other
hand, women are less likely than men to develop colon cancer,
and estrogen hormone replacement therapy further reduces the
incidence of colorectal cancer in postmenopausal women. Col-
lectively, estrogen appears to be protective for colorectal cancer
development (Lawrence et al., 2007; Weige et al., 2009). Men are
more prone to develop skin cancers including squamous cell car-
cinomas and melanoma. The skin has gender-specific differences
that may explain this disparity (Giacomoni et al., 2009). Ultravio-
let exposure and stress induce immunosuppression in the human
skin (Streilein et al., 1994), and this effect is stronger in males
(Damian et al., 2008; Reeve et al., 2012). The higher incidence
of thyroid and gallbladder tumors in women seem to be a nat-
ural consequence of higher prevalence of benign thyroid disease
and gallbladder stones, which are known to be risk factors for
these cancers (Edgren et al., 2012). Why benign thyroid disease
and gallbladder stones are more common in females is, however,
unknown. The main physiologic differences between males and
females are caused by sex hormones, and these will be discussed
later.
The importance of exploring the mechanism of the gender
effect in cancer susceptibility is manifold. Besides identifying the
subpopulations at higher risk to implement preventive measures,
and learning about disease biology for prevention as well as ther-
apeutic interventions, we may also clarify some paradoxical phe-
nomena. Lung cancer provides an interesting example for the last
point. In absolute numbers many more men develop and die from
lung cancer, but this does not mean they are more susceptible.
Studies of molecular mechanisms of lung cancer development in
males and females to test the earlier suggestions that females may
actually have greater inherent susceptibility to lung cancer, yielded
positive results. It has now been widely accepted that although
males have higher morbidity and mortality rates for lung cancer,
women are at greater risk to develop it (Kiyohara and Ohno, 2010).
The higher incidence rate in males is due to higher frequency of
smoking.
DIFFERENCES IN REGULATION OF GENE EXPRESSION BETWEEN
MALES AND FEMALES
Since gene expression changes are the most common intermediate
phenotype underlying variable disease risk (Nica and Dermitza-
kis, 2008; Cookson et al., 2009; Murphy et al., 2010), such changes
may also be responsible for differential risk between males and
females. Sexual dimorphism in gene expression has been repeat-
edly documented in animals and humans (Shriver et al., 2000;
Ostrer, 2001; Rinn et al., 2004; Rinn and Snyder, 2005; Clodfel-
ter et al., 2006; Yang et al., 2006; Isensee and Ruiz Noppinger,
2007; Isensee et al., 2008; Penaloza et al., 2009; van Nas et al.,
2009; Mank et al., 2010; Zhang et al., 2011; Arnold and Lusis,
2012; Conforto and Waxman, 2012). This dimorphism extends
beyond simple transcript abundance and concerns the organiza-
tion of gene expression networks (van Nas et al., 2009). In more
detailed studies, few autosomal genes are constitutively sex-biased
throughout different time points, and a minority of genes change
the direction of sex bias (Mank et al., 2010). It may sound implau-
sible, but the most comprehensive sex-specific gene expression
studies in mice identified a surprisingly large number of signif-
icant differences in gene expression between the sexes, ranging
from a few hundred to more than ten thousand in the different
tissues examined (Yang et al., 2006). Many of the genes that were
identified have been implicated in various common diseases in
which disease susceptibility is sex-biased.
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Table 3 | Physiologic and genomic differences between males and females that may be relevant to differential cancer susceptibility.
Trait PubMed ID
Transcriptional sexual dimorphism in preimplantation embryos due to lack of X
chromosome inactivation at that stage
20501630; 21339284
Greater fetal growth rate and higher birth weight in males 8300805; 17344203
Higher endothelin-1 blood levels in males 8439117
Higher gastrin-releasing peptide receptor (GRPR) levels in females 10620630
Higher leptin levels in females from birth to adulthood 12105281
Higher iron stores in males 21161013
Immunologic functions are stronger in females 517475; 6228595
Immunomodulatory effects of vitamin D(3) are stronger in females than in males 20855882
Gene expression level differences in autosomal as well as sex chromosome genes 10620630; 11641384; 15177028; 15851067; 16469768; 16825664;
17646949; 19190082; 18974276; 20142440; 21858147; 22434084;
19190082; 18156105
Long-range transcriptional regulatory elements associated with chromatin structure
(correlating with sex-specific gene expression levels)
20876297
Higher methylation levels in males 17851693
Overall higher recombination rates in female germ cells (except at the telomeres of
chromosomes where male recombination rates are higher)
9718341
Differences in alternative splicing 20009012
Higher level of DNA damage in males 12297147
Higher in vitro gamma-ray-induced chromatid breaks in males 10856961
Lower DNA repair capacity in females 11058619; 19065660; 18845243; 12917198; 20022891
Higher baseline micronucleus or micronucleated binucleate cell frequency in females 11170240; 9729354
Higher CYP1A1 expression and DNA adduct levels in the lung of female smokers 16557573
Higher lipid peroxidation in females 12142263
Gene expression at the mRNA level does not always correlate
with protein expression. What matters is whether sex-specific gene
expression differences are translated into the protein level. Just
like transcriptomic studies examining gene expression levels at
the mRNA level, studies comparing the proteome of males and
females also found remarkable sex differences (Arnold and Lusis,
2012). A recent human study revealed striking sex differences in
serum metabolite concentrations, with 102 out of 131 metabolites
differing significantly between males and females. This variation
also correlated with specific genetic variants in metabolism-related
genes (Mittelstrass et al., 2011). Thus, sexual dimorphism most
commonly examined at the gene expression levels appear to be
present also at the metabolomic and proteomic level.
EPIGENETIC MECHANISM
There are known differences in epigenetic profiles of autosomal
and sex chromosome genes between the sexes and in age groups
(El-Maarri et al., 2007; Tobi et al., 2009; reviewed in Yuasa, 2010).
Environmental and lifestyle factors also influence the epigenome
(Brait et al., 2009; Bollati and Baccarelli, 2010; Waterland et al.,
2010; Yuasa, 2010), some with sex-specificity (Tobi et al., 2009).
Thus, epigenetic phenomena are likely to underlie the gender
differences in cancer. There is currently no report implicating
epigenetic changes in the sex disparity in cancer susceptibility,
but future epigenetic epidemiology studies are likely to test these
possibilities (Foley et al., 2009; Relton and Davey Smith, 2010).
Epigenetic studies have also examined the tumor samples directly.
An interesting finding was the male-specific hypermethylation of
RASSF1A, but not the other genes under study (Vaissiere et al.,
2009). Further examination of such clues is also likely to provide
further insight into the gender differences in cancer susceptibility.
IMMUNE SURVEILLANCE DIFFERENCES BETWEEN MALES AND
FEMALES
Immune surveillance has now been recognized as a major physi-
ologic mechanism protecting our bodies from cancer progression
(Swann and Smyth, 2007; Eyles et al., 2010; Cramer and Finn,
2011). Since sexual dimorphism in immune response capacity
is also well recognized, the differences in immune surveillance
competence between males and females should contribute to the
gender effect in cancer incidence. Generally, females mount higher
innate and adaptive immune responses than males, which can
result in faster clearance of pathogens but also contributes to
increased susceptibility to inflammatory and autoimmune diseases
in females compared with males. The expression of X-linked genes
and microRNA (miRNA), as well as sex steroid hormones signaling
through hormone receptors in immune cells can affect responses
to immunological stimuli differently in males and females possi-
bly resulting in male-female differential in incidence rates of not
only cancer, but also infectious diseases, inflammatory disorders,
autoimmune diseases, and vaccine responses (Klein, 2012).
Hormonal effects on immune surveillance
Both estrogens and androgens have been recognized as modula-
tors of immune response and determinants of gender differences
in disease susceptibility (Table 4; Olsen and Kovacs, 1996; Klein,
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Table 4 | Effects of sex hormones on immune system*.
Estrogens Androgens
Overall : enhanced immune response Overall : diminished immune
response
Enhanced antibody-mediated
responses to exogenous antigens
Decreased antibody
production
Enhanced T-cell cytotoxicity Decreased T-cell proliferation
Increased cytokine and chemokine
levels (including increased
interferon-gamma production)
Alteration of cytokine profile
of activated T-cells to
decrease inflammation
(including decreased
interferon-gamma production)
Decreased IL-6 production Increased IL-6 and IL-10
production
Enhanced antigen presenting cell
activation
Decreased MHC class II
antigen expression on antigen
presenting cells
Stronger innate immune responses by
promoting the differentiation of
IFN-gamma-producing killer dendritic
cells or by up-regulation of inducible
nitric oxide synthase expression and
nitric oxide production
Reduced inducible nitric oxide
synthase expression and
nitric oxide production
*Reviewed in Olsen and Kovacs (1996), Martin (2000), Lin et al. (2010), Ghazeeri
et al. (2011), Karpuzoglu and Zouali (2011), Klein (2012), Pennell et al. (2012).
2012; Pennell et al., 2012). Sex hormones have been shown to
modulate gene expression in vitro (cell line studies), and in vivo
(gene expression profiling in animal and human cells and tissues).
Their effects on target tissues are mediated by intracellular sex hor-
mone receptors (Scheller et al., 1998; Kato et al., 2005; Heldring
et al., 2007). Estrogen receptors (ERs) are present in B and T lym-
phocytes, neutrophils, macrophages, NK cells, bone marrow, and
thymic stromal cells. Two types of ERs, ER-alpha and ER-beta have
different functions despite having similar structures. Membrane-
bound forms of ERs have different functions and are present on
mature lymphocytes. ER-alpha is also expressed in dendritic cells,
which can regulate the quality of the adaptive immune responses
(Kovats, 2012). The effect of sex steroids on immune cell func-
tions are generally achieved by their influences on cell signaling
pathways, including nuclear factor-κB (NF-κB) and interferon
regulatory factors (Kalaitzidis and Gilmore, 2005). Although not
frequently mentioned, estrogen effects on the immune system may
be dosage-dependent (Pennell et al., 2012).
Besides regulation of immune cell activity through direct action
mediated by their receptors, estrogen also selectively regulates reg-
ulatory miRNA expression in immune cells with functional con-
sequences (Dai et al., 2008). Intracellular and membrane-bound
androgen receptors are expressed in B and T lymphocytes (Sader
et al., 2005). Non-gonadal (adrenal) steroids act through their
glucocorticoid receptors which are strongly expressed by immune
cells. It has been suggested that their sexually dimorphic actions
may be linked to diseases with different prevalence in males and
females (Duma et al., 2010). Besides, they show tissue-specific dif-
ferences in their expression on immune cells. In addition to sex
hormones’ contribution to sex differences, indirect effects can be
mediated by growth hormone as well. For example, the well estab-
lished sexual dimorphism in liver gene expression is due to growth
hormone action (Clodfelter et al., 2006; Waxman and Holloway,
2009).
Sex chromosome-related effects on immune surveillance
Males have one copy of the X chromosome as opposed to females
having two copies. To achieve gene dosage adjustment, X chro-
mosome inactivation takes place. In each female cell, one of the
X chromosomes is randomly inactivated. As a result, the same X
chromosome is expressed in approximately 50% of female cells. If
an X chromosome gene has a mutation or a deleterious polymor-
phism, all male cells will lack its protein product, but 50% of female
cells may still have the functional protein provided that the other
copy of the gene is functional. This is how an X chromosome gene
mutations may have different effects on males and females and why
this is usually the first explanation considered for a male-female
differential in any physiologic phenomenon or a trait. Having just
one copy of the X chromosome in males has been likened to the
inbreeding depression where the protective effects of heterozygote
advantage are lost (Morris and Harrison, 2009).
Identifying X chromosome-linked susceptibility causing gen-
der disparity in cancer occurrence may be possible by examining
large cancer registries in countries where excellent records exist
and are linked to birth registries. In examination of cancer inci-
dence in children of cancer cases, higher frequency of cancer in
daughters of male cases compared with sons would implicate the
contribution of an X chromosome gene to susceptibility. In an
extensive survey of Denmark Cancer Registry, X chromosome-
linked genetic factors were not found responsible for the excess
risk of cancer in males (Biggar et al., 2009). However, these efforts
aim to identify genetic risk factors for familial cancers, and nega-
tive findings do not rule out the presence of low penetrance genetic
contributions to sporadic cancer occurrence.
The X chromosome contains the largest number of immune-
related genes of the whole human genome (Fish, 2008; Libert et al.,
2010; Pinheiro et al., 2011; Bianchi et al., 2012). Given the expres-
sion differences between males and females of the genes in sex
chromosomes, it is expected that X chromosome-linked immune
regulatory genes have important roles in mediating the sexual
dimorphism in immune response. It has been shown that one of
those genes, TLR7, is expressed at a higher level in females than in
males with functional consequences (Berghofer et al., 2006). The
X chromosome is not only enriched in immune regulatory genes,
but also miRNAs with roles in the immune system (Pinheiro et al.,
2011). The cumulative effects of the immune regulatory genes
and miRNAs should be an important contributor to the differ-
ences in immune surveillance capacity between males and females
underlying the differences in cancer susceptibility.
Growing evidence supports a regulatory cascade concept of sex-
ual dimorphism in gene expression. This concept proposes that the
initiating events of sexual differentiation during embryonic devel-
opment trigger differential expression in many mediator genes that
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regulate the sexually dimorphic expression of downstream genes
such as transcription factors and signaling molecules (Clodfel-
ter et al., 2006; Bermejo-Alvarez et al., 2011). Epigenetic alteration
mediated by sex chromosome genes is another mechanism for gen-
der difference in autosomal gene expression (Wijchers and Festen-
stein, 2011). Sex chromosome genes can more directly contribute
to sex differences too (Arnold and Burgoyne, 2004). Indirect evi-
dence suggests a possible role of sex chromosome-linked genes in
the regulation of sexual dimorphism. There is a generalized sex
chromosome enrichment of the sexually dimorphic genes in all
tissues examined, and a significant portion of common dimor-
phic genes across tissues are X- or Y-linked (Yang et al., 2006). Sex
chromosome genes showing sex-biased expression may thus serve
as candidate regulators (Yang et al., 2006).
The recently developed mouse model system used to identify
effects of the sex chromosome complement without the confound-
ing effects of differences in gonadal type has provided convincing
evidence that sex chromosomes have effects on sexual dimorphism
in autoimmunity independent of sex hormones (Palaszynski et al.,
2005). This model system allows comparisons between XX and XY-
(Sry-deficient) within a female hormonal background, as well as
between XXSry and XY-Sry within a male hormonal background.
The disease-promoting effect of the XX sex chromosome com-
plement has been shown in this model for animal equivalents of
multiple sclerosis and systemic lupus erythematosus. The expected
sexual dimorphism in the immune system was also evident to a
degree in this model which examines the correlations of genotypes
with two different sex chromosome complements which exist in
equivalent hormonal status (Smith-Bouvier et al., 2008). Thus,
the female sex chromosome complement, as compared with the
male sex chromosome complement, has a direct effect on pro-
moting susceptibility to two autoimmune diseases with strong
female predominance, and this effect is unlikely to be mediated by
indirect effects of differences in sex hormones in this model. How-
ever, the earlier study showed that the XY-genotype is relatively
immunostimulatory, compared with the XX genotype, confirming
that it is the male hormone phenotype which is immunoinhibitory
(Palaszynski et al., 2005).
In another cell line model, untreated male and female cells
of the same age respond differently to the stressors, even before
the production of fetal sex hormones (Penaloza et al., 2009).
These findings also suggest independent effects of sex chro-
mosomes, which is probably due to programming during early
developmental stages (Bermejo-Alvarez et al., 2011).
GENOMIC SURVEILLANCE DIFFERENCES BETWEEN MALES AND
FEMALES
As listed in Table 3, there are known physiologic differences
between males and females that are relevant to the efficiency of
genomic surveillance mechanisms. However, there is no clear pat-
tern regarding why males have overall greater cancer susceptibility,
or why females have higher incidence rates for few cancers. A recent
review has noted that “too few studies are available to draw firm
conclusions” (Kirsch-Volders et al., 2010).
MOLECULAR CLUES FOR GENDER DIFFERENCES IN TWO CANCERS
Childhood ALL is more common in males, and examples of
gender-specific associations have been presented (Table 2). One
of the gender-specific associations concerns the interferon regu-
latory factor-4 (IRF4) locus (Do et al., 2010). An intronic SNP
(rs12203592) shows a male-specific association (OR= 4.4, 95%
CI= 1.5–12.6). In the experiments aimed to functionally repli-
cate this association, the wildtype allele of the SNP showed a
repressive effect on the transcription of IRF4. The variant allele,
which is the risk allele for leukemia, lacked the repressive effect.
This meant that the risk allele was associated with increased tran-
scription of IRF4. IRF4 has a deleterious effect on leukemia and
this result was biologically plausible. The explanation of the gen-
der effect involved the influence of estrogen on the transcription
factor NF-kappa B (NFkB), which regulates IRF4 transcription.
Because estrogen has an inhibitory effect on NFkB, and males
lack this effect, the combination of this with the possession of
the variant allele were thought to be the reason for increased
IRF4 production that results in the male-specific risk associa-
tion. During childhood estrogen and androgen levels are very
low and not much different between males and females (Ober
et al., 2008). This suggests prenatal programming of sex hormone
effect on autosomal gene expression. Likewise, the association
of a MDM2 promoter region SNP with age-at-onset of child-
hood leukemia only in females (Do et al., 2009) suggests prenatal
programming of gene expression regulation by estrogen signal-
ing since this MDM2 association is attributed to the effect of
this SNP on estrogen action on the gene expression (Bond et al.,
2006).
Thyroid cancer is one of the few cancers that are more common
in females. Not just the incidence, but also the tumor aggres-
siveness and prognosis show gender difference (Rahbari et al.,
2010). While the exact mechanism of the female preponderance is
unknown, androgen receptor expression in thyroid follicular cells
through which androgens reduce proliferation of follicular cells
may be a possible mechanism. Lacking this effect, females may
be at higher risk of developing thyroid follicular cancer (Stan-
ley et al., 2012). Furthermore, estrogens induce thyroid cancer
cell proliferation and enhance anti-apoptotic potential (Lee et al.,
2005). Despite possible involvement of sex hormones in thyroid
cancer development, however, sex hormone gene variants failed
to show any association with thyroid cancer risk (Schonfeld et al.,
2012).
CONCLUSION
The differences between males and females begin even before
implantation of the zygote in the uterus. The differences continue
throughout prenatal development phases, in childhood and adult-
hood. These differences generate a lot of contrasts, and variation
in disease susceptibility is one of them. There are many common
diseases that are more common in males or females. In cancer,
susceptibility is generally higher in males although some cancers
are more common in women. The same is true for autoimmunity
in which females have an overall higher susceptibility, but males
are more susceptible for few of them. The endogenous causes of
the gender differences observed in diseases are largely unknown,
and the situation in cancer research is not much different. Over
the last decade, a lot of progress has been made in the field some
of which are due to the advent of omics techniques. If the research
community is convinced about the presence of gender differences
in disease susceptibility, regardless of the techniques used, even
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more progress should be expected during the next decade. In this
review, we presented data generated in different fields including
descriptive and genetic epidemiology, physiology, and genetical
genomics. Multidisciplinary efforts using the appropriate ana-
lytical approaches should unravel many remaining mysteries of
gender differences in cancer susceptibility.
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